Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-07 |
2024-03 |
0.64 |
0.62 |
-0.02 |
-3.13% |
2024-02-29 |
2023-12 |
0.89 |
0.89 |
N/A |
N/A |
2023-11-02 |
2023-09 |
0.84 |
0.72 |
-0.12 |
-14.29% |
2023-08-02 |
2023-06 |
0.81 |
0.78 |
-0.03 |
-3.70% |
2023-05-03 |
2023-03 |
0.6 |
0.53 |
-0.07 |
-11.67% |
2023-02-28 |
2022-12 |
0.8 |
0.8 |
N/A |
N/A |
Date |
Firm |
Action |
From |
To |
2023-10-02 |
RBC Capital |
Upgrade |
Outperform |
Outperform |
2023-08-02 |
Needham |
Upgrade |
Buy |
Buy |
2023-08-02 |
HC Wainwright & Co. |
Upgrade |
Buy |
Buy |
2023-08-02 |
TD Cowen |
Upgrade |
Market Perform |
Outperform |
2023-08-02 |
RBC Capital |
Upgrade |
Outperform |
Outperform |
2023-08-02 |
Truist Securities |
Upgrade |
Buy |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2023-06-13 |
BREGE LAURA A |
Director |
11.32K |
Stock Award(Grant) |
2024-02-04 |
GAUGLER DARYL |
Chief Operating Officer |
65.49K |
Stock Award(Grant) |
2023-06-13 |
HASTINGS PAUL J |
Director |
8.37K |
Stock Award(Grant) |
2024-01-01 |
LEE FRANK DON |
Chief Executive Officer |
99.52K |
Stock Award(Grant) |
2024-03-07 |
PACE GARY WILLIAM |
Director |
22.13K |
Sale |
2023-07-04 |
RIKER LAUREN BULLARO |
Officer |
22.69K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Blackrock Inc. |
7.48M |
299.78M |
16.12% |
2023-06-29 |
Vanguard Group Inc |
4.95M |
198.44M |
10.67% |
2023-06-29 |
State Street Corporation |
1.72M |
68.85M |
3.70% |
2023-06-29 |
Frontier Capital Management Company LLC |
1.69M |
67.53M |
3.63% |
2023-06-29 |
Baillie Gifford and Company |
1.66M |
66.46M |
3.57% |
2023-06-29 |
Renaissance Technologies, LLC |
1.57M |
63.10M |
3.39% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-09-29 |
iShares Core S&P Smallcap ETF |
3.13M |
96.15M |
6.75% |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
1.36M |
54.38M |
2.92% |
2023-06-29 |
Vanguard Small-Cap Index Fund |
1.13M |
45.20M |
2.43% |
2023-08-30 |
iShares Russell 2000 ETF |
1.04M |
36.80M |
2.25% |
2023-07-30 |
Legg Mason Clearbridge Small Cap Growth Fd |
923.64K |
33.57M |
1.99% |
2023-07-30 |
Vanguard Explorer Fund, Inc. |
647.80K |
23.55M |
1.40% |